Searched for
ONCOLOGY PORTFOLIO
Biocon gets USFDA nod for breast cancer biosimilar PebrilzoBiocon Ltd has announced receiving US FDA approval for their biosimilar Pebrilzo, which treats HER2-positive breast cancer. This milestone ...
For investors with patience and ability to take moderate risk: 5 mid-cap stocks with upside potential of up to 26%For all those who have decided it is now time to turn bullish, here’s a small reminder: The past year has been a very tough one for mid-cap...
These large-, mid- and small-cap stocks have upside potential of more than 20% in 1 year, according to analystsThe probability of a sharp, damaging downturn now appears low, and the broad direction favours the market. So, the stance should be the sam...
For investors with medium-term outlook: 5 large-cap stocks with upside potential of up to 23%, according to analystsThe headwinds hitting the market are not just easing now. Some of them are actually turning into tailwinds. That is a real change. The broa...
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%The FPIs that were selling in the Indian market all these months mostly owned large-cap stocks. And as they sold them, it was that segment ...
More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger rolesIndia's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers bus...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28% in 1 year, according to analystsDespite the upbeat mood in the market, remember one thing: Valuations are still not cheap. Even after everything the market has been throug...
These large-, mid- and small-cap stocks have upside potential of up to 31% in 1 year, according to analystsIn the last two years, the world has learnt that you can never quite predict what US President Trump will do next. Tomorrow, to pull attent...
Zydus Q2 profit falls 27% despite 29% revenue growth; consumer wellness sales surge 76%Zydus Lifesciences reported a 29% year-on-year rise in Q2FY27 revenue to Rs 7,909 crore, driven by growth across key markets and a 76% surg...
4 stocks with consistent score improvement and upside potential of up to 31% in 1 year, according to analystsAlthough the indices are in the green on Monday, the market is extremely volatile. The upmove is being attributed to some recovery in oil p...
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trialJohnson & Johnson reported results from an early-stage trial of their prostate cancer drug JNJ-6143. The trial involved patients with advan...
5 stocks with consistent score improvement and upside potential of up to 29% in 1 year, according to analystsDo not paint the whole market with one brush. Even in an extended fall like the current one, some parts of the economy still manage to hold...
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up 32%, according to analystsHistory tells us that there is no way you can time the markets or predict its movement. But one thing can certainly be said: If the macro m...
5 stocks with consistent score improvement and upside potential of up to 29 % in 1 year, according to analystsLook at how the market treated the stock of a large FMCG stock – one the best wealth creators of the past – just because it mentioned the r...
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsThe next few weeks are critical, and one should not be in a hurry to make market-related decisions. Better to be cautious – to wait and wat...
CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 20%In times like these, the market will have its green and red days. What matters, however, is not the colour of a single day, but the things ...